BRCA2 and cancer: For example, reversion mutations or epigenetic alterations leading to the re‐expression of a BRCA1 or BRCA2 wild‐type protein or resulting in hypomorphic variants are common resistance mechanisms to PARPi, which is also the main mechanism for platinum resistance in BRCA1/2‐mutated cancer [14].